8-K: SI-BONE Announces Strong Preliminary Revenue Growth and Adjusted EBITDA Profitability for Q4 and Full Year 2024

SI-BONE reports preliminary unaudited revenue growth of approximately 26% for the fourth quarter of 2024 and achieves adjusted EBITDA profitability.

Summary

• SI-BONE has released preliminary unaudited financial results for the fourth quarter and full year of 2024.
• Worldwide revenue for Q4 2024 is estimated to be between $48.8 and $49.0 million, representing a growth of approximately 26% compared to the same period last year.
• U.S. revenue for Q4 2024 is estimated to be between $46.7 and $46.9 million, showing a growth of approximately 28%.
• The company ended the quarter with approximately 1,390 active physicians in the U.S., which is a 23% increase year-over-year.
• SI-BONE's cash and marketable securities are approximately $150 million, with a net cash use of about $0.8 million in the quarter.
• For the full year 2024, worldwide revenue is estimated to be between $167.0 and $167.1 million, representing a growth of approximately 20%.
• Full year U.S. revenue is estimated to be between $158.2 and $158.4 million, showing a growth of approximately 21%.
• The company achieved adjusted EBITDA profitability in the fourth quarter.
• These results are preliminary and subject to adjustments after the completion of financial closing and audit procedures.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, adjusted EBITDA profitability, and an increase in active physicians. However, the preliminary nature of the results and the inherent risks in the medical device industry temper the overall optimism.

Positives

• SI-BONE experienced strong revenue growth in both the fourth quarter and full year of 2024.
• The company achieved adjusted EBITDA profitability in the fourth quarter, a significant milestone.
• There was a substantial increase in the number of active physicians using SI-BONE's products in the U.S.
• The company maintains a strong cash position with approximately $150 million in cash and marketable securities.

Negatives

• The preliminary results are subject to adjustments after the completion of financial closing and audit procedures.
• The company had a net cash use of approximately $0.8 million in the fourth quarter.

Risks

• The preliminary financial results are subject to change pending final review by the company and its auditors.
• The company's ability to introduce and commercialize new products and indications is a risk.
• Maintaining favorable reimbursement for procedures using SI-BONE's products is a risk.
• Economic weakness could impact patients' willingness to undergo elective procedures.
• Supply chain risks could affect the company's operations.
• Future capital requirements for new surgical systems could impact the company's finances.
• The pace of healthcare environment normalization could affect procedure volumes.

Future Outlook

SI-BONE expects continued revenue and procedure growth, but these expectations are subject to risks and uncertainties, including the finalization of financial results and market conditions.

Management Comments

• SI-BONE believes the presentation of adjusted EBITDA is useful to management because it allows management to more consistently analyze period-to-period financial performance.
• SI-BONE also believes the presentation of adjusted EBITDA is useful to investors and other interested persons as it enables these persons to use this additional information to assess the company's performance.

Industry Context

This announcement indicates strong growth for SI-BONE in the medical device sector, particularly in the area of sacropelvic disorders. The company's focus on minimally invasive procedures and its expanding physician network are key drivers of this growth. This performance could position SI-BONE favorably against competitors in the same space.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, SI-BONE's 26% revenue growth in Q4 and 20% for the full year are strong indicators of performance in the medical device industry.
• Companies like Globus Medical and NuVasive, which also operate in the spinal and orthopedic space, have seen varying growth rates, but SI-BONE's focus on sacropelvic disorders provides a niche market.
• The achievement of adjusted EBITDA profitability in Q4 is a positive sign, as many medical device companies focus on growth over immediate profitability in their early stages.
• The 23% growth in active physicians suggests a strong adoption rate of SI-BONE's technologies, which is a key metric for success in this industry.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and adjusted EBITDA profitability.
• Employees may be encouraged by the company's positive performance and growth.
• Customers (physicians) are likely to continue adopting SI-BONE's technologies given the growth in active physicians.
• Suppliers may see increased demand for SI-BONE's products.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• SI-BONE will complete its financial closing procedures and audit procedures by its external auditors.
• The company will provide final fourth quarter and full year 2024 financial results during its fourth quarter 2024 earnings call in late February 2025.

Key Dates

Keywords

SI-BONE, Sacropelvic Disorders, Medical Devices, Revenue Growth, Adjusted EBITDA, Physician Growth, Financial Results, Surgical Treatment, Minimally Invasive Surgery, Cash Position